PROVIDING THE 'ON' SWITCH FOR IMMUNO-ONCOLOGY
DEAD

Serial Number

87623162

Owner

Replimune Limited

Attorney

Melanie Howard

Filing Date

Sep 26, 2017

Add to watchlist:

No watchlists yet
View on USPTO

PROVIDING THE 'ON' SWITCH FOR IMMUNO-ONCOLOGY Trademark

Serial Number: 87623162 • Registration: 5517469

PROVIDING THE 'ON' SWITCH FOR IMMUNO-ONCOLOGY is a trademark filed by Replimune Limited on September 26, 2017. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

Replimune Limited (14 trademarks)

69 Innovation Dr., Milton Park, Abingdon
Oxfordshire OX144RQ , GB

Entity Type: 99

Trademark Details

Filing Date

September 26, 2017

Registration Date

July 17, 2018

Published for Opposition

May 1, 2018

Cancellation Date

February 4, 2025

Goods & Services

Biological preparations in the nature of viruses for the treatment of cancer, tumors, infectious, oncological, autoimmune, and immune system diseases and disorders; biological preparations in the nature of viruses for the treatment of cancer; biological preparations in the nature of viruses for inducing immune response; pharmaceuticals, namely, pharmaceutical preparations and pharmaceutical substances for the treatment of cancer, tumors, infectious, oncological, autoimmune, and immune system diseases and disorders; pharmaceuticals, namely, anti-infectives for the treatment of cancer, tumors, infectious, oncological, autoimmune, and immune system diseases and disorders; pharmaceuticals for the treatment of cancer; pharmaceutical preparations for inducing immune response; vaccines; immunotherapy products, namely, pharmaceutical products for the prevention and treatment of cancer, tumors, infectious, oncological, autoimmune, and immune system diseases and disorders; gene therapy products, namely, therapeutics for the treatment of cancer, tumors, infectious, oncological, autoimmune, and immune system diseases and disorders

Pharmaceutical drug research and development services; research and development of vaccines and medicines; information, advisory and consultancy services relating to the aforesaid

Filing History

CANCELLED SEC. 8 (6-YR)
Feb 4, 2025 C8..
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Jul 17, 2023 REM1
REGISTERED-PRINCIPAL REGISTER
Jul 17, 2018 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 1, 2018 NPUB
PUBLISHED FOR OPPOSITION
May 1, 2018 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 11, 2018 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 29, 2018 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 20, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 20, 2018 CRFA
ASSIGNED TO LIE
Mar 14, 2018 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 1, 2018 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 3, 2018 GNRN
NON-FINAL ACTION E-MAILED
Jan 3, 2018 GNRT
NON-FINAL ACTION WRITTEN
Jan 3, 2018 CNRT
ASSIGNED TO EXAMINER
Jan 3, 2018 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 30, 2017 NWOS
NEW APPLICATION ENTERED
Sep 29, 2017 NWAP